AptarGroup (ATR) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Aptar published the results on October 29, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Aptar reports EPS two ways: GAAP, under the accounting rules every US filer follows, and adjusted, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Aptar deconsolidated its Russian subsidiary in Q3 2026 after a government decree put it under external administration. The $61.2 million pre-tax impact cut GAAP EPS by $0.94; adjusted EPS excludes it.
• The year-ago adjusted EPS of $1.62 is the figure Aptar presents at comparable exchange rates.

Source: Aptar Q3 2026 results, October 29, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Aptar splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Aptar's Pharma revenue was $454 million in Q3 2026, up 2% from $445 million in Q3 2025, 45% of total revenue.
• Aptar's Beauty revenue was $357 million in Q3 2026, up 9% from $328 million in Q3 2025, 35% of total revenue.
• Aptar's Closures revenue was $208 million in Q3 2026, up 11% from $188 million in Q3 2025, 20% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Aptar said:

“Aptar currently expects adjusted earnings per share for the fourth quarter of 2026 to be in the range of $1.39 to $1.47.”

“This guidance assumes an effective tax rate range of 17.5% to 19.5%.”

“The earnings per share guidance range is assuming a 1.12 Euro to USD exchange rate.”

Source: Aptar Q3 2026 release, Oct 29, 2026.

This is the company's own guidance as of Oct 29, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the ATR forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP net sales and diluted EPS, each as first reported in that quarter's release.

We do not hold a confirmed date for Aptar's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 29, 2026

Aptar's net sales rose 6% to $1,019.1 million in Q3 2026, and core sales, which exclude currency effects, acquisitions and the Russian subsidiary, rose 5%. Pharma brought in $454.0 million, Beauty $357.4 million and Closures $207.8 million. (Aptar Q3 2026 release, Oct 29, 2026; Aptar Form 10-Q, Q3 2026, Oct 30, 2026)

Pharma's reported sales rose 2% and core sales 1%. Core sales to the prescription drug market fell 7%, mainly because of the anticipated drop in emergency medicine sales; Aptar says Pharma core sales grew 8% adjusting for that destocking. Consumer health care core sales rose 13% on nasal decongestant and dermal drug delivery demand, and injectables rose 9% on elastomeric components used for GLP-1 therapies, biologics and vaccines. (Aptar Q3 2026 release, Oct 29, 2026; Aptar Form 10-Q, Q3 2026, Oct 30, 2026)

Beauty's core sales grew 8%, with demand for prestige fragrance dispensing, color cosmetics and hair care, and pass-throughs of higher input costs. Closures' core sales grew 11%, led by beverage and food: bottled water, concentrates, condiments and Aptar's newer beverage dispensing closures. (Aptar Q3 2026 release, Oct 29, 2026)

Europe is Aptar's largest market. Of the quarter's net sales, Europe accounted for $501.4 million, the domestic U.S. market $299.6 million, Asia $128.8 million and Latin America $89.4 million. Pharma alone sold $215.2 million in Europe. (Aptar Form 10-Q, Q3 2026, Oct 30, 2026)

Aptar's GAAP diluted EPS fell to $0.51 from $1.92, while adjusted EPS was $1.52 against $1.62 a year earlier at comparable exchange rates. The gap is mostly the Russian deconsolidation: a $58.0 million loss, including about $30.0 million of cash held by the subsidiary, plus receivable reserves and legal costs, for a combined $60.4 million after tax, or $0.94 per diluted share. Adjusted EPS also excludes restructuring, investment losses and litigation costs Aptar classes as other special items ($0.04). (Aptar Q3 2026 release, Oct 29, 2026)

Because the deconsolidation loss is largely non-deductible, the reported effective tax rate was 45.6%; the adjusted rate was 23.4%, against 20.8% a year earlier. The year-ago GAAP figure was lifted by a $26.5 million gain from remeasuring an equity method investment. (Aptar Q3 2026 release, Oct 29, 2026)

Diluted shares fell to 64,147 thousand from 66,630 thousand. Aptar repurchased about 234 thousand shares for $30 million in the quarter, returned $272 million to shareholders year-to-date through buybacks and dividends, and raised its quarterly dividend to $0.50 from $0.48. (Aptar Q3 2026 release, Oct 29, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Aptar gives one-quarter-ahead adjusted EPS guidance in its release. For Q4 2026 it expects adjusted EPS of $1.39 to $1.47, assuming an effective tax rate of 17.5% to 19.5% and a 1.12 euro to U.S. dollar exchange rate. Aptar said Q3 adjusted EPS of $1.52 came in at the higher end of its prior guidance range. (Aptar Q3 2026 release, Oct 29, 2026)

The CEO said Aptar expects continued Pharma growth in the fourth quarter, particularly in consumer healthcare and injectables, without the headwind from emergency medicine destocking. Aptar gives no GAAP EPS outlook, citing items such as exchange rates and restructuring that it cannot predict. (Aptar Q3 2026 release, Oct 29, 2026)

A consensus figure is the average of the models published by the analysts who cover Aptar, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Aptar's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning ATR is on is ATR a buy or a sell?, what analysts expect next is on the ATR forecast, and what the company does is on the AptarGroup (ATR) stock page.

Every number on this page can be traced to a document Aptar published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.